Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 1999

View Archived Issues

Interneuron: FY 1998 results

MorphoSys enters licensing agreement with Chiron for HuCAL

Actinova enters collaboration for development of tooth decay treatment

Results of animal studies indicate ability of GeneSwitch to regulate gene therapy

Chugai presents new COX-2 inhibitor series

Compounds for depression and other CNS disorders reported by Akzo Nobel

Improved treatments for BPH in development at Pfizer

Novel squalene synthase inhibitors claimed by Nippon Kayaku

Several setbacks reported with Lundbeck antipsychotic

Integrin receptor antagonists, prodrugs and transdermal iontophoretic administration

Medeva launches Anthra's valrubicin in first market

Unigene obtains E.U. approval for injectable calcitonin product

Bayer claims camptothecin glycoconjugates for use in cancer

Potent and selective DAT ligand identified by RTI and Emory University

Rochester Medical files PMA for FemSoft

Telmisartan reaches U.S. pharmacy shelves

Terprenin: novel immunosuppressant and antiallergic substance under evaluation at Shionogi

FDA grants priority review to SB's Avandia

Japanese group discovers novel microbial metabolite with antitumor and immunosuppressive effects

Cel-Sci and University of Maryland receive award for TB vaccine development

Genzyme collaborates with Canadian researchers to develop cardiovascular disease therapies

Mitsubishi Chemical and Tokyo Tanabe to merge

Vertex initiates phase II psoriasis trial of VX-497

Snow Brand reports new developments concerning cevimeline

Avant receives patent coverage for complement inhibitors

Celebrex approved in first market outside U.S.

PAP mutants licensed by Hughes Institute; potential anticancer and antiviral therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...